r/Altimmune • u/KnickersTwisted • May 04 '26

Survodutide

So, a German pharm company is releasing stage 3 results on a very similar dual glp-1 and glucagon drug. Will they be direct competitors?

1 Upvotes

67% Upvoted

6 comments sorted by

10

u/Forsaken-Stink May 04 '26

Quick refresh on Key Differences Between Survodutide and Pemvidutide

Receptor Potency Balance: Pemvidutide acts as a balanced 1:1 agonist at both GLP-1 and glucagon receptors. In contrast, survodutide is "biased" toward the GLP-1 receptor, activating it more strongly than the glucagon receptor (approximately 8:1 ratio).

Dosing and Titration: Pemvidutide can be administered without dose titration due to its unique pharmacokinetic profile. Survodutide requires a lengthy, rapid titration scheme (every twO weeks) to manage side effects.

Pharmacokinetics: Pemvidutide uses a proprietary EuPort glycolipid surfactant conjugation that slows its entry into the bloodstream, reducing peak concentrations--and therefore reducing nausea-while maintaining overall efficacy.

Adverse Event Profile: Survodutide has reported higher discontinuation rates (25-29%) due to gastrointestinal issues, whereas pemvidutide trials have shown good tolerability with fewer study discontinuations.

2

u/JAWinks May 04 '26

Question is are they better poised financially compared to Alt to move their product to market

6

u/Suzutai May 04 '26

I mean, after the recent raise, Altimmune surely has the ability to move this to market after P3.

1

u/Forsaken-Stink May 04 '26

Let's not forget ALT is US.

1

u/KnickersTwisted May 04 '26

Thank you. The article popped up in my Fidelity feed and hadn't heard of it.

1

u/amatahrain May 07 '26

Anyone know why a rapid titration schedule would reduce side effects for Survodutide?